Management

Johannes Swartling

CEO 

Shares

356 405 shares (incl. relatives)

Johannes Swartling has a Ph.D. in physics from Lund University (2002). He has worked at SpectraCure since 2006 and is responsible for research and development at the company. He has experience in development of medical devices, clinical trials, and quality and regulatory work including risk management. Before joining SpectraCure AB, he held post-doctoral research positions at Politecnico di Milano, Italy, and at Cambridge University, UK. His research has been on applications of laser technology and spectroscopy in biology and medicine, His research has been on applications of laser technology and spectroscopy in biology and medicine, and he is the author of some 30 original peer-reviewed research papers.

Kristina Holst
Head of Clinical Affairs
Shares

29 667 shares

Kristina Holst is a licensed dentist. She has many years of experience in the medical technology industry and has mainly worked with clinical studies but also with marketing and product development. Kristina has previously held leading positions in clinical studies and regulatory activities at, among others, Arjo, Medeuronet, DMC Healthcare and Straumann.

Fata Mrsic 

CFO
Shares:

0 shares

Fata Mrsic holds a degree in Business Controlling from Lund University and has more than 20 years of experience in finance, accounting, and business controlling. She has held key positions in both publicly listed companies and fast-growing growth businesses, where she has contributed to financial strategy, governance, and operational finance. Fata also serves as Chief Financial Officer (CFO) of Lumito AB. 

Marcelo Soto Thompson 

CTO
Shares:

113 334 shares (incl. relatives)

Master of Science in Engineering Physics (1999) and PhD in Physics (2004) from Lund University. Marcelo Soto Thompson has a background in the research group at Atomic Physics at Lund University that took part the founding of SpectraCure, where he was one of original founders. Marcelo has worked with technology development at companies in, among other places, the United States, and was recruited back to SpectraCure in 2016 to play a key role in the development of the Q-PRO® platform, SpectraCure’s new generation of equipment for the treatment of prostate cancer using photodynamic therapy.